Janssen signs $847m lung cancer immunotherapy deal with Aduro
This article was originally published in Scrip
Janssen has signed its second deal with California's Aduro BioTech, this time paying $30m upfront and agreeing to milestone payments of up to $817m for rights to lung cancer products developed using Aduro's immunotherapy platform.
You may also be interested in...
Both Janssen and Aduro gradually realized the Listeria technology platform was not delivering hoped-for results. Aduro will not continue the projects abandoned by Janssen, and will focus on its STING and APRIL programs going forward.
Immuno-oncology deals command relatively high values, but transaction volumes are increasing annually at a steady pace, not skyrocketing despite intense interest in the field as big pharma companies remain selective IO dealmakers based on the strength of early-stage data.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.